You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Trading Tips.
Forget the narrative for a second. Here are real figures from real companies, all pulled from their most recent reported quarters:
- One name grew Q1 revenue ~49% year over year, lifted gross margin to 43%, and holds about $174.9 million in cash and investments against zero total debt.
- Another is sitting on a $22.7 billion backlog, roughly $2 billion in cash, no debt — and just swung from a year-ago loss to $9 million in net income while more than doubling adjusted EBITDA to $78 million.
- A semiconductor-test leader more than doubled its top line year over year ($686M → $1.282B) and reported GAAP EPS of $2.53. Analysts currently model roughly 40.3% revenue growth and 82.9% EPS growth for 2026.
- A medical robotics player grew U.S. procedure volume about 30%, runs a 65% gross margin, and reaffirmed full-year guidance implying 27%–33% revenue growth.
These aren't story stocks living on hope. In several cases the market is paying up because the earnings are already showing up in the numbers.
The free report names all seven, breaks down each balance sheet and growth profile, and — just as important — tells you which ones are expensive, which charts look broken, and where the execution risk sits. No fluff.
Click here to get your free copy of this report
By clicking this link you agree to receive emails from Trading Tips and our affiliates. You can opt out at any time. - Privacy Policy
